<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03931109</url>
  </required_header>
  <id_info>
    <org_study_id>829615</org_study_id>
    <nct_id>NCT03931109</nct_id>
  </id_info>
  <brief_title>Circulating miRNA in Primary Hyperparathyroidism</brief_title>
  <official_title>Circulating microRNA Signatures in Primary Hyperparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to: 1. Analyze the expression levels of circulating (serum) miRNAs
      in primary hyperparathyroidism patients with and without osteoporosis, and patients with
      osteoporosis undergoing thyroidectomy, and to correlate with clinical markers of bone
      remodeling including biochemical and radiologic studies. 2. To evaluate serum miRNA levels
      after treatment with parathyroidectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoporosis and osteopenia are chronic diseases disproportionately affecting the elderly. In
      the United States, the prevalence of osteoporosis is projected to increase from 10 million in
      2005 to 14 million in 2025, due to population aging. Similarly, the economic cost of
      osteoporotic fractures is projected to increase to $25 billion by 2025. Primary
      hyperparathyroidism (PHPT) is one of the few reversible causes of osteoporosis and fragility
      fractures. PHPT is the third most common endocrine disorder, with an incidence of 27-30 per
      100,000 person-years, and increasing with age; half of all patients with PHPT are
      post-menopausal women, a population at high risk for osteoporosis at baseline. All forms of
      PHPT are characterized by loss of the normal negative feedback relationship between serum
      calcium and parathyroid hormone (PTH) secretion, leading to hypercalcemia and
      hyperparathyroidism. Classic PHPT is characterized by skeletal, renal, gastrointestinal and
      neuropsychiatric manifestations. Skeletal manifestations of classic PHPT are mediated by
      osteoblast inhibition and osteoclast stimulation, leading to increased bone remodeling. The
      catabolic effects of chronic PTH excess may present as osteitis fibrosa cystica, brown
      tumors, pathologic fractures, bone pain, osteoporosis or osteopenia. Although frank osteitis
      fibrosa cystica is an increasingly rare presentation of PHPT in the United States, affecting
      2% of patients, osteoporosis is reported in 39-63% of patients, with preferential loss of
      bone density in cortical sites. Fragility fractures are significantly associated with PHPT,
      particularly in postmenopausal women. Both decreases in bone mineral density (BMD) and
      fragility fractures are considered indications for parathyroidectomy in patients with
      asymptomatic PHPT. Parathyroidectomy has been demonstrated to improve BMD in prospective
      studies of PHPT patients with osteoporosis; some studies suggest that more benefit may be
      seen in pre-menopausal women. Current research in bone remodeling has identified microRNAs
      (miRNAs), novel biomarkers with both diagnostic and therapeutic potential. miRNAs are short,
      single stranded, non-coding RNAs which regulate posttranscriptional expression of mRNA.
      miRNAs have been extensively implicated in bone remodeling and homeostasis. Circulating
      miRNAs have been shown to correlate with fragility fractures, and are conserved across
      subpopulations of osteoporotic patients. miRNA panels have been suggested to have the
      potential to assist in diagnosis, prognosis, and are promising targets for directed therapy.
      Although miRNAs have been investigated in conjunction with pre-menopausal, postmenopausal,
      idiopathic and diabetic osteoporosis, no research to date has explored the miRNA profile of
      PHPT patients with osteoporosis. Similarly, although in vitro experiments have demonstrated
      miRNA response to bisphosphonates, no clear correlation has been established between
      therapeutic interventions and miRNA levels in vivo. The goal of this study is therefore
      two-fold; first, to analyze the expression levels of circulating miRNAs in PHPT patients with
      and without osteoporosis; and second, to evaluate miRNA levels after treatment with
      parathyroidectomy.

      This is a prospective, non-randomized pilot study. Post-menopausal female subjects with and
      without osteoporosis, undergoing neck surgery or non-operative management will be recruited.
      Informed consent will be obtained. Venipuncture will be performed and serum and plasma
      isolated from study subjects. Analysis of serum miRNA and biochemical and clinical markers of
      bone remodeling will be performed. Clinical care will proceed as planned. Subjects undergoing
      surgery will be reassessed one year after operative intervention for miRNA and clinical and
      biochemical markers.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 7, 2018</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>circulating microRNAs in primary hyperparathyroidism patients</measure>
    <time_frame>2019-2021</time_frame>
    <description>Serum miRNA levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum miRNA after parathyroidectomy</measure>
    <time_frame>2019-2021</time_frame>
    <description>clinical markers of bone remodeling, including serum levels of bone-specific alkaline phosphatase, osteocalcin, P1NP, CTX, calcium, phosphate, Vitamin D metabolites, and PTH; urine calcium; and DXA scan</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Primary Hyperparathyroidism</condition>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>PHPT w/ Osteoporosis</arm_group_label>
    <description>Primary hyperparathyroidism patients with osteoporosis undergoing parathyroidectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PHPT w/o Osteoporosis</arm_group_label>
    <description>Primary hyperparathyroidism patients without osteoporosis undergoing parathyroidectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thyroid w/ Osteoporosis</arm_group_label>
    <description>Thyroid disease patients with osteoporosis undergoing thyroidectomy</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        post-menopausal women diagnosed with primary hyperparathyroidism.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  post menopausal

          -  has had DXA scan

          -  has 24 hr Urine Calcium

          -  Elevated serum calcium

          -  Vitamin D above 20 ng/ml

          -  capable of giving informed consent

          -  female

          -  indication for biochemical primary hyperparathyroidism or an indication for partial or
             total thyroidectomy

        Exclusion Criteria:

          -  history of ESRD on dialysis or renal osteodystrophy

          -  prior parathyroidectomy

          -  hyper or hypothyroid by TSH

          -  currently taking steroids or has been on steroids for more than 7 days in the last two
             years

          -  estrogen therapy within the last two years

          -  bisphosphonate therapy within the last two years

          -  diagnosis of Cushing's disease or Cushing's syndrome

          -  taking biotin within 24 hours of blood draw
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather Wachtel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Perelman Center for Advanced Medicine/ Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007 Mar;22(3):465-75.</citation>
    <PMID>17144789</PMID>
  </reference>
  <reference>
    <citation>Fraser WD. Hyperparathyroidism. Lancet. 2009 Jul 11;374(9684):145-58. doi: 10.1016/S0140-6736(09)60507-9. Review.</citation>
    <PMID>19595349</PMID>
  </reference>
  <reference>
    <citation>Lewiecki EM, Miller PD. Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. J Clin Densitom. 2013 Jan-Mar;16(1):28-32. doi: 10.1016/j.jocd.2012.11.013. Review.</citation>
    <PMID>23374738</PMID>
  </reference>
  <reference>
    <citation>Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol. 2018 Feb;14(2):115-125. doi: 10.1038/nrendo.2017.104. Epub 2017 Sep 8. Review.</citation>
    <PMID>28885621</PMID>
  </reference>
  <reference>
    <citation>De Geronimo S, Romagnoli E, Diacinti D, D'Erasmo E, Minisola S. The risk of fractures in postmenopausal women with primary hyperparathyroidism. Eur J Endocrinol. 2006 Sep;155(3):415-20.</citation>
    <PMID>16914595</PMID>
  </reference>
  <reference>
    <citation>Vignali E, Viccica G, Diacinti D, Cetani F, Cianferotti L, Ambrogini E, Banti C, Del Fiacco R, Bilezikian JP, Pinchera A, Marcocci C. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2009 Jul;94(7):2306-12. doi: 10.1210/jc.2008-2006. Epub 2009 Apr 28.</citation>
    <PMID>19401378</PMID>
  </reference>
  <reference>
    <citation>Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab. 2014 Oct;99(10):3561-9. doi: 10.1210/jc.2014-1413. Epub 2014 Aug 27.</citation>
    <PMID>25162665</PMID>
  </reference>
  <reference>
    <citation>Lundstam K, Heck A, Godang K, Mollerup C, Baranowski M, Pernow Y, Aas T, Hessman O, Rosén T, Nordenström J, Jansson S, Hellström M, Bollerslev J; SIPH Study Group. Effect of Surgery Versus Observation: Skeletal 5-Year Outcomes in a Randomized Trial of Patients With Primary HPT (the SIPH Study). J Bone Miner Res. 2017 Sep;32(9):1907-1914. doi: 10.1002/jbmr.3177. Epub 2017 Jul 7.</citation>
    <PMID>28543873</PMID>
  </reference>
  <reference>
    <citation>Lumachi F, Camozzi V, Ermani M, DE Lotto F, Luisetto G. Bone mineral density improvement after successful parathyroidectomy in pre- and postmenopausal women with primary hyperparathyroidism: a prospective study. Ann N Y Acad Sci. 2007 Nov;1117:357-61. Epub 2007 Jul 23.</citation>
    <PMID>17646261</PMID>
  </reference>
  <reference>
    <citation>Kim KM, Lim SK. Role of miRNAs in bone and their potential as therapeutic targets. Curr Opin Pharmacol. 2014 Jun;16:133-41. doi: 10.1016/j.coph.2014.05.001. Epub 2014 Jun 5. Review.</citation>
    <PMID>24907412</PMID>
  </reference>
  <reference>
    <citation>Garnero P. New developments in biological markers of bone metabolism in osteoporosis. Bone. 2014 Sep;66:46-55. doi: 10.1016/j.bone.2014.05.016. Epub 2014 Jun 5. Review.</citation>
    <PMID>24909537</PMID>
  </reference>
  <reference>
    <citation>Jing D, Hao J, Shen Y, Tang G, Li ML, Huang SH, Zhao ZH. The role of microRNAs in bone remodeling. Int J Oral Sci. 2015 Sep 14;7(3):131-43. doi: 10.1038/ijos.2015.22. Review.</citation>
    <PMID>26208037</PMID>
  </reference>
  <reference>
    <citation>Heilmeier U, Hackl M, Skalicky S, Weilner S, Schroeder F, Vierlinger K, Patsch JM, Baum T, Oberbauer E, Lobach I, Burghardt AJ, Schwartz AV, Grillari J, Link TM. Serum miRNA Signatures Are Indicative of Skeletal Fractures in Postmenopausal Women With and Without Type 2 Diabetes and Influence Osteogenic and Adipogenic Differentiation of Adipose Tissue-Derived Mesenchymal Stem Cells In Vitro. J Bone Miner Res. 2016 Dec;31(12):2173-2192. doi: 10.1002/jbmr.2897. Epub 2016 Sep 26.</citation>
    <PMID>27345526</PMID>
  </reference>
  <reference>
    <citation>Kocijan R, Muschitz C, Geiger E, Skalicky S, Baierl A, Dormann R, Plachel F, Feichtinger X, Heimel P, Fahrleitner-Pammer A, Grillari J, Redl H, Resch H, Hackl M. Circulating microRNA Signatures in Patients With Idiopathic and Postmenopausal Osteoporosis and Fragility Fractures. J Clin Endocrinol Metab. 2016 Nov;101(11):4125-4134. Epub 2016 Aug 23.</citation>
    <PMID>27552543</PMID>
  </reference>
  <reference>
    <citation>Weilner S, Skalicky S, Salzer B, Keider V, Wagner M, Hildner F, Gabriel C, Dovjak P, Pietschmann P, Grillari-Voglauer R, Grillari J, Hackl M. Differentially circulating miRNAs after recent osteoporotic fractures can influence osteogenic differentiation. Bone. 2015 Oct;79:43-51. doi: 10.1016/j.bone.2015.05.027. Epub 2015 May 28.</citation>
    <PMID>26026730</PMID>
  </reference>
  <reference>
    <citation>Hackl M, Heilmeier U, Weilner S, Grillari J. Circulating microRNAs as novel biomarkers for bone diseases - Complex signatures for multifactorial diseases? Mol Cell Endocrinol. 2016 Sep 5;432:83-95. doi: 10.1016/j.mce.2015.10.015. Epub 2015 Oct 23. Review.</citation>
    <PMID>26525415</PMID>
  </reference>
  <reference>
    <citation>Zhou Q, Zhao ZN, Cheng JT, Zhang B, Xu J, Huang F, Zhao RN, Chen YJ. Ibandronate promotes osteogenic differentiation of periodontal ligament stem cells by regulating the expression of microRNAs. Biochem Biophys Res Commun. 2011 Jan 7;404(1):127-32. doi: 10.1016/j.bbrc.2010.11.079. Epub 2010 Nov 23.</citation>
    <PMID>21108928</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2019</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>primary hyperparathyroidism</keyword>
  <keyword>miRNA</keyword>
  <keyword>Bone remodeling</keyword>
  <keyword>parathyroidectomy</keyword>
  <keyword>Osteopenia</keyword>
  <keyword>postmenopausal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
    <mesh_term>Hyperparathyroidism</mesh_term>
    <mesh_term>Hyperparathyroidism, Primary</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03931109/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03931109/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

